Compounds > phe-cyclo(cys-tyr-trp-lys-val-cys)thr-nh2
Page last updated: 2024-09-03

phe-cyclo(cys-tyr-trp-lys-val-cys)thr-nh2 and Cancer of Prostate

phe-cyclo(cys-tyr-trp-lys-val-cys)thr-nh2 has been researched along with Cancer of Prostate in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19903 (50.00)18.7374
1990's1 (16.67)18.2507
2000's2 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Halmos, G; Letsch, M; Nagy, A; Schally, AV; Szepeshazi, K1
Arencibia, JM; Halmos, G; Koppan, M; Nagy, A; Plonowski, A; Schally, AV1
Halmos, G; Nagy, A; Plonowski, A; Schally, AV; Sun, B1
Redding, TW; Schally, AV2
Paz-Bouza, JI; Redding, TW; Schally, AV; Zalatnai, A1

Other Studies

6 other study(ies) available for phe-cyclo(cys-tyr-trp-lys-val-cys)thr-nh2 and Cancer of Prostate

ArticleYear
Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.
    The Journal of urology, 2004, Volume: 171, Issue:2 Pt 1

    Topics: Androgens; Animals; Bone Neoplasms; Cell Line, Tumor; Cytotoxins; Doxorubicin; Drug Carriers; Humans; Male; Mice; Mice, Nude; Octreotide; Prostatic Neoplasms; Pyrroles; Somatostatin

2004
Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
    Cancer research, 1998, Sep-15, Volume: 58, Issue:18

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Screening Assays, Antitumor; Male; Octreotide; Prostatic Neoplasms; Pyrroles; Rats; Receptors, Somatostatin; Tumor Cells, Cultured

1998
Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
    International journal of oncology, 2002, Volume: 20, Issue:2

    Topics: Animals; Antibiotics, Antineoplastic; Cell Division; Cytotoxins; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Octreotide; Prostatic Neoplasms; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Treatment Outcome; Tumor Cells, Cultured

2002
Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Proceedings of the National Academy of Sciences of the United States of America, 1987, Volume: 84, Issue:20

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Capsules; Drug Compounding; Drug Synergism; Gonadotropin-Releasing Hormone; Male; Octreotide; Organ Size; Prostate; Prostatic Neoplasms; Rats; Somatostatin; Triptorelin Pamoate

1987
Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH.
    The Prostate, 1988, Volume: 12, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Epithelium; Gonadotropin-Releasing Hormone; Luteinizing Hormone; Male; Octreotide; Organ Size; Prolactin; Prostate; Prostatic Neoplasms; Rats; Somatostatin; Testis; Testosterone; Triptorelin Pamoate

1988
Use of analogs of LH-RH and somatostatin for the treatment of hormone dependent cancers.
    Progress in clinical and biological research, 1988, Volume: 262

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Capsules; Gonadotropin-Releasing Hormone; Humans; Injections, Intramuscular; Male; Mammary Neoplasms, Experimental; Neoplasms, Hormone-Dependent; Octreotide; Pancreatic Neoplasms; Prostatic Neoplasms; Rats; Somatostatin; Triptorelin Pamoate

1988